SCIENTURE HOLDINGS, INC. Business Acquisition, Pro Forma Revenue
SCIENTURE HOLDINGS, INC. (SCNX) reported Business Acquisition, Pro Forma Revenue of $636.64 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2026-03-30
- SCIENTURE HOLDINGS, INC. business acquisition, pro forma revenue for the quarter ending 2024-12-31 was $53.08K, a 58.74% decline year-over-year.
- SCIENTURE HOLDINGS, INC. business acquisition, pro forma revenue for the quarter ending 2024-09-30 was $64.86K.
- SCIENTURE HOLDINGS, INC. business acquisition, pro forma revenue for the quarter ending 2024-06-30 was $18.70K.
- SCIENTURE HOLDINGS, INC. business acquisition, pro forma revenue for the quarter ending 2024-03-31 was $1.86M.
- SCIENTURE HOLDINGS, INC. business acquisition, pro forma revenue for fiscal 2024 was $636.64K, a 65.84% decline from fiscal 2023.
- SCIENTURE HOLDINGS, INC. business acquisition, pro forma revenue for fiscal 2023 was $1.86M.
- SCIENTURE HOLDINGS, INC. business acquisition, pro forma revenue for fiscal 2018 was $5.82M, a 4.65% increase from fiscal 2017.
- SCIENTURE HOLDINGS, INC. business acquisition, pro forma revenue for fiscal 2017 was $5.57M.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 9 month as first filed | Business Acquisition, Pro Forma Revenue 12 month | Business Acquisition, Pro Forma Revenue 12 month as first filed |
|---|---|---|---|---|---|---|
| 2024-12-31 | $53.08K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $117.94K derived: sum of 2 quarters · filed 2026-03-30 | $136.64K derived: sum of 3 quarters · filed 2026-03-30 | $636.64K 10-K · filed 2026-03-30 | $136.64K 10-K · filed 2025-03-26 | |
| 2024-09-30 | $64.86K 10-Q · filed 2025-11-12 | $83.56K derived: sum of 2 quarters · filed 2025-11-12 | $583.56K 10-Q · filed 2025-11-12 | $83.56K 10-Q · filed 2024-11-06 | $2.08M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $18.70K 10-Q · filed 2025-08-12 | $518.70K 10-Q · filed 2025-08-12 | $2.01M derived: sum of 3 quarters · filed 2025-08-12 | |||
| 2024-03-31 | $1.86M 10-Q · filed 2025-05-12 | $1.99M derived: sum of 2 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | $128.66K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $1.86M 10-K · filed 2025-03-26 | ||||
| 2023-09-30 | $1.74M 10-Q · filed 2024-11-06 | |||||
| 2019-03-31 | $1.50M 10-Q · filed 2019-05-13 | $2.80M derived: sum of 2 quarters · filed 2020-03-30 | $4.31M derived: sum of 3 quarters · filed 2020-03-30 | $5.82M derived: sum of 4 quarters · filed 2020-03-30 | ||
| 2018-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | $2.81M derived: sum of 2 quarters · filed 2020-03-30 | $4.33M derived: sum of 3 quarters · filed 2020-03-30 | $5.82M 10-K · filed 2020-03-30 | ||
| 2018-09-30 | $1.51M 10-Q · filed 2019-10-28 | $3.03M derived: sum of 2 quarters · filed 2019-10-28 | $4.52M 10-Q · filed 2019-10-28 | |||
| 2018-06-30 | $1.52M 10-Q · filed 2019-07-26 | $3.01M 10-Q · filed 2019-07-26 | ||||
| 2017-12-31 | $5.57M 10-K · filed 2019-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |